SCOTUS to weigh 'materiality proof' question in Amgen class action case
This article was originally published in Scrip
Executive Summary
The US Supreme Court on 11 June said it would hear an appeal from Amgen claiming a lower court erred when it said a group of investors could move forward with a securities fraud class-action lawsuit alleging the biotech giant downplayed the US FDA's safety concerns about Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) and caused the firm's stock prices to be inflated.